Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

which faced market challenges against established Covid-19 vaccine leaders like Pfizer and Moderna. However, Novavax’s ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

With a market cap of $18 billion, Moderna is at the forefront of innovative healthcare solutions, pioneering treatments for ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

The CDC urges both an updated COVID-19 shot and yearly flu vaccine for everyone ages 6 months and older ... to a new section ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Pfizer’s and Moderna's vaccine has been updated over time to ... 2 and KP.3. What is the circulating COVID-19 strain in Tennessee? Updated data for Davidson County Across the United States ...